0001209191-23-045366.txt : 20230811
0001209191-23-045366.hdr.sgml : 20230811
20230811074004
ACCESSION NUMBER: 0001209191-23-045366
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230810
FILED AS OF DATE: 20230811
DATE AS OF CHANGE: 20230811
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chambers Michael Andrew
CENTRAL INDEX KEY: 0001932527
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 231161554
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-10
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001932527
Chambers Michael Andrew
215 FIRST STREET SUITE 415
CAMBRIDGE
MA
02142
1
0
0
0
0
Common Stock
2023-08-10
4
P
0
2206
104.67
A
180670
I
By Revocable Trust
Common Stock
2023-08-10
4
P
0
1091
105.90
A
181761
I
By Revocable Trust
Common Stock
2023-08-10
4
P
0
31570
106.26
A
213331
I
By Revocable Trust
Common Stock
6431
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $103.99 to $104.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105 to $106, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.01 to $106.83, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
/s/ Ryan Brown, as Attorney-in-Fact for Michael Chambers
2023-08-11